"TBSF" Human Immunoglobulin for Intravenous Use

Šalis: Australija

kalba: anglų

Šaltinis: Department of Health (Therapeutic Goods Administration)

Veiklioji medžiaga:

normal immunoglobulin, Quantity: 60 g/L

Prieinama:

CSL Behring Australia Pty Ltd

INN (Tarptautinis Pavadinimas):

normal immunoglobulin

Vaisto forma:

Injection, solution

Sudėtis:

Excipient Ingredients: maltose

Vartojimo būdas:

Intravenous

Vienetai pakuotėje:

50mL, 200mL

Klasė:

Medicine Listed (Export Only)

Recepto tipas:

(S1) This Schedule is intentionally blank

Terapinės indikacijos:

TBSF Human Immunoglobulin for Intravenous Use is indicated for replacement IgG therapy in: * primary immunodeficiency (PID) * symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. TBSF Human Immunoglobulin for Intravenous Use is indicated for immunomodulatory therapy in: * Idiopathic Thrombocytopenic Purpura (ITP), in adults or children at high risk of bleeding or prior to surgery to correct the platelet count * allogeneic bone marrow transplantation * Kawasaki disease * Guillain-Barre Syndrome (GBS).

Produkto santrauka:

Visual Identification: Clear, colourless solution; Container Type: Vial; Container Life Time: 3 Years; Container Temperature: Store at 2 to 8 degrees Celsius

Autorizacija statusas:

Listed (Export Only)

Leidimo data:

2006-03-01